Timothy MD - Dice Molecules Chief Officer

Insider

Timothy MD is Chief Officer of Dice Molecules Holdings
Age 49
Phone650 566 1402
Webhttps://www.dicemolecules.com

Dice Molecules Management Efficiency

The company has return on total asset (ROA) of (0.1402) % which means that it has lost $0.1402 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.216) %, meaning that it created substantial loss on money invested by shareholders. Dice Molecules' management efficiency ratios could be used to measure how well Dice Molecules manages its routine affairs as well as how well it operates its assets and liabilities.
100%
Dice Molecules Holdings currently holds 13.27 M in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Dice Molecules Holdings has a current ratio of 23.14, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Dice Molecules' use of debt, we should always consider it together with its cash and equity.
Cash95.51%100%

Similar Executives

Showing other executives

INSIDER Age

Hal MDPliant Therapeutics
N/A
Bahija JallalImmunocore Holdings
64
Senthil SundaramTerns Pharmaceuticals
46
Justin KleeAmylyx Pharmaceuticals
34
Kari JDCytokinetics
N/A
CMO MBAViridian Therapeutics
72
Badreddin EdrisEdgewise Therapeutics
37
Oxana BeskrovnayaDyne Therapeutics
64
Charles IIDay One Biopharmaceuticals
47
Chris MBACrinetics Pharmaceuticals
N/A
John NussVentyx Biosciences
66
Rami ElghandourArcellx
46
Debra CannerAmylyx Pharmaceuticals
65
Prof ShairNuvalent
56
Christopher MDArcellx
45
Liean MSAcumen Pharmaceuticals
N/A
Ashish MBAVaxcyte
53
Todd IRCViridian Therapeutics
N/A
Birgitte MDAscendis Pharma AS
62
MBA MDViridian Therapeutics
72
Jaa RobersonDay One Biopharmaceuticals
N/A
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company was incorporated in 2013 and is headquartered in South San Francisco, California. Dice Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 61 people. Dice Molecules Holdings (DICE) is traded on NASDAQ Exchange in USA and employs 71 people.

Management Performance

Dice Molecules Holdings Leadership Team

Elected by the shareholders, the Dice Molecules' board of directors comprises two types of representatives: Dice Molecules inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dice. The board's role is to monitor Dice Molecules' management team and ensure that shareholders' interests are well served. Dice Molecules' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dice Molecules' outside directors are responsible for providing unbiased perspectives on the board's policies.
Kevin Judice, CEO Founder
Scott Robertson, Chief Officer
Timothy MD, Chief Officer
John Jacobsen, Chief Officer
Mary JD, G Counsel
Venkat Thalladi, VP CMC
Paul Fatheree, VP Chemistry

Dice Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dice Molecules a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Other Consideration for investing in Dice Stock

If you are still planning to invest in Dice Molecules Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dice Molecules' history and understand the potential risks before investing.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges